New t cell engager takes on tough colorectal cancer
Disease control
Recruiting now
This early-phase trial tests a new drug called CBI-1214 in 80 people with advanced colorectal cancer that has not responded to standard treatments. CBI-1214 is designed to connect the body's own immune T cells to cancer cells, helping the immune system attack the tumor. The main …
Phase: PHASE1 • Sponsor: Cartography Biosciences • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC